Skip to main content
Journal cover image

Transition to oral beta-lactam therapy in uncomplicated gram-negative bacteremia: A systematic review and meta-analysis.

Publication ,  Journal Article
Dore, M; Duffy, R; Caputo, L; Huang, L; Sidoti, S; Cantrell, S; Glasgo, B; Kerbow, C
Published in: J Hosp Med
August 2025

INTRODUCTION: Gram-negative bacteremia (GNB) is associated with significant morbidity and mortality. Transition to oral therapy has traditionally utilized fluoroquinolones or trimethoprim-sulfamethoxazole rather than beta-lactams due to concerns about pharmacokinetics and bioavailability despite a dearth of clinical data. The purpose of this meta-analysis is to evaluate the clinical efficacy of transition to oral beta-lactam therapy in uncomplicated GNB. METHODS: We performed a meta-analysis of published articles in MEDLINE, Embase, and Web of Science databases from inception to September 2024. Inclusion criteria included any study with adults (age >18 years of age) with uncomplicated GNB from any source. Primary outcomes included 30-day all-cause mortality and 30-day antibiotic failure rate. RESULTS: Eight retrospective cohort studies were reviewed comprising 7500 patients. Twice as many patients were in the fluoroquinolones/trimethoprim-sulfamethoxazole group compared with the beta-lactams group (4998 vs. 2482). Patients in each group had similar average age (70 vs. 71), percent male (54% vs. 56%), percent urinary source (78% vs. 80%), duration of IV antibiotics (4.2 vs. 4.5), Pitt bacteremia score (1.1 vs. 1.4) and Charleston comorbid index (2 vs. 2). There was no statistically significant difference in the 30-day all-cause mortality rate between the fluoroquinolones/trimethoprim-sulfamethoxazole and the beta-lactams group: 2.06% versus 1.89% with a weighted relative risk ratio of 1.24 (95% confidence interval [CI]: 0.86-1.77) or the 30-day antibiotic failure rate: 2.08% vs. 3.42%, weighted relative risk ratio of 1.29 (95% CI: 0.97-1.71). CONCLUSIONS: There is no statistically significant difference in 30-day mortality or antibiotic failure rates between BL and FQ/TMP-SMX as transition to oral therapy in treating uncomplicated GNB.

Duke Scholars

Published In

J Hosp Med

DOI

EISSN

1553-5606

Publication Date

August 2025

Volume

20

Issue

8

Start / End Page

866 / 873

Location

United States

Related Subject Headings

  • beta-Lactams
  • Trimethoprim, Sulfamethoxazole Drug Combination
  • Humans
  • Gram-Negative Bacterial Infections
  • General & Internal Medicine
  • Fluoroquinolones
  • Bacteremia
  • Anti-Bacterial Agents
  • Administration, Oral
  • 4205 Nursing
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Dore, M., Duffy, R., Caputo, L., Huang, L., Sidoti, S., Cantrell, S., … Kerbow, C. (2025). Transition to oral beta-lactam therapy in uncomplicated gram-negative bacteremia: A systematic review and meta-analysis. J Hosp Med, 20(8), 866–873. https://doi.org/10.1002/jhm.70041
Dore, Michael, Ryan Duffy, Laura Caputo, Lily Huang, Salvatore Sidoti, Sarah Cantrell, Blair Glasgo, and Christa Kerbow. “Transition to oral beta-lactam therapy in uncomplicated gram-negative bacteremia: A systematic review and meta-analysis.J Hosp Med 20, no. 8 (August 2025): 866–73. https://doi.org/10.1002/jhm.70041.
Dore M, Duffy R, Caputo L, Huang L, Sidoti S, Cantrell S, et al. Transition to oral beta-lactam therapy in uncomplicated gram-negative bacteremia: A systematic review and meta-analysis. J Hosp Med. 2025 Aug;20(8):866–73.
Dore, Michael, et al. “Transition to oral beta-lactam therapy in uncomplicated gram-negative bacteremia: A systematic review and meta-analysis.J Hosp Med, vol. 20, no. 8, Aug. 2025, pp. 866–73. Pubmed, doi:10.1002/jhm.70041.
Dore M, Duffy R, Caputo L, Huang L, Sidoti S, Cantrell S, Glasgo B, Kerbow C. Transition to oral beta-lactam therapy in uncomplicated gram-negative bacteremia: A systematic review and meta-analysis. J Hosp Med. 2025 Aug;20(8):866–873.
Journal cover image

Published In

J Hosp Med

DOI

EISSN

1553-5606

Publication Date

August 2025

Volume

20

Issue

8

Start / End Page

866 / 873

Location

United States

Related Subject Headings

  • beta-Lactams
  • Trimethoprim, Sulfamethoxazole Drug Combination
  • Humans
  • Gram-Negative Bacterial Infections
  • General & Internal Medicine
  • Fluoroquinolones
  • Bacteremia
  • Anti-Bacterial Agents
  • Administration, Oral
  • 4205 Nursing